Aptose Biosciences Inc. (NASDAQ:APTO) Sees Large Decrease in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 54,900 shares, a decline of 35.9% from the March 31st total of 85,600 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily volume of 93,500 shares, the days-to-cover ratio is presently 0.6 days.

Aptose Biosciences Stock Performance

NASDAQ APTO opened at $1.16 on Friday. The company has a market cap of $18.24 million, a P/E ratio of -0.15 and a beta of 1.29. The business’s 50 day moving average price is $1.56 and its 200-day moving average price is $2.12. Aptose Biosciences has a fifty-two week low of $1.15 and a fifty-two week high of $8.70.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings data on Tuesday, March 26th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.48) by $0.04. As a group, equities analysts predict that Aptose Biosciences will post -3.31 EPS for the current year.

Institutional Trading of Aptose Biosciences

Several institutional investors have recently added to or reduced their stakes in APTO. Sigma Planning Corp bought a new stake in Aptose Biosciences in the third quarter worth about $408,000. Annandale Capital LLC grew its holdings in shares of Aptose Biosciences by 40.0% in the third quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 21,334 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Aptose Biosciences in the fourth quarter worth about $32,000. Institutional investors own 26.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on APTO shares. Piper Sandler reaffirmed an “overweight” rating and issued a $5.00 target price on shares of Aptose Biosciences in a report on Wednesday, April 3rd. StockNews.com upgraded shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, March 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, March 27th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.80.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.